OnKure Therapeutics, Inc. — Director's Dealing 2021

Dec 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-12-10

Reporting Person: FLESHER GREGORY J. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-10	Common Stock	A	100000	$0.00	Acquired	109600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-10	Stock option (right to buy)	$6.69	A	200000	Acquired	2031-12-09	Common Stock (200000)	Direct

Footnotes

F1: Represents a restricted stock unit award.

F2: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2021.

F3: The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.